title: Can SLC19A1 80G>A polymorphisms predict risk of extremely delayed MTX excretion after high dose of methotrexate?
authors.forename: Maria Moeller
authors.initials: MM
authors.lastname: Rasmussen
authors.forename: Regitse Hoejgaard
authors.initials: RH
authors.lastname: Christensen
authors.forename: Jannie
authors.initials: J
authors.lastname: Gregers
authors.forename: Jesper
authors.initials: J
authors.lastname: Heldrup
authors.forename: Jacob
authors.initials: J
authors.lastname: Nersting
authors.forename: Kjeld
authors.initials: K
authors.lastname: Schmiegelow
mesh_terms: D002648:Child; D005838:Genotype; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000378:metabolism*; D020641:Polymorphism, Single Nucleotide; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D058978:Reduced Folate Carrier Protein / Q000235:genetics*
chemical_list: D058978:Reduced Folate Carrier Protein; C548699:SLC19A1 protein, human; D008727:Methotrexate